Boehringer Ingelheim Overview
Pro stress-test →Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates globally with more than 54,000 employees in 76 countries. The company's key areas of interest are respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system.
Strategic Profile
Pro stress-test →The company is private and fully owned by the Boehringer, Liebrecht and von Baumbach families, enabling long-term strategic investments without public market pressure. As a family-owned pharmaceutical company, Boehringer Ingelheim is able to take a long-term view and invest heavily in research and development. The company balances human pharmaceuticals (81% of sales) with animal health and biopharmaceutical contract manufacturing divisions.
Competitive Landscape
Pro stress-test →Boehringer Ingelheim competes with other top-20 global pharmaceutical companies in respiratory, cardiovascular, metabolic, oncology, and immunology segments. Key competitors include Roche, Novartis, Merck, AbbVie, Bristol Myers Squibb, and Eli Lilly. Unlike most large peers, Boehringer's private status allows differentiated long-term R&D investment and strategic flexibility, while its animal health and contract manufacturing divisions provide competitive diversification.
Industry Context
Boehringer Ingelheim operates in Pharmaceuticals.
Key facts
Founded: 1885 · Headquarters: Ingelheim am Rhein, Germany · Employees: 54,300 · Revenue: €27.8B (2025)